Business Context and Reporting Period
Company: DiaMedica Therapeutics Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: July 21, 2025
Reporting Period: Event-based (July 21, 2025)
Business Context: The Company, incorporated in British Columbia, Canada, and trading on Nasdaq under the symbol "DMAC," entered into a material definitive agreement for a private placement of equity securities.
Key Financial Metrics
Transaction Details:
- Shares Issued: 8,606,426 common shares.
- Purchase Price: $3.50 per share.
- Gross Proceeds: Approximately $30.1 million (before fees and expenses).
- Expected Closing Date: On or about July 23, 2025.
Use of Proceeds:
- Continuation of the preeclampsia clinical development program for DM199.
- Working capital and general corporate purposes.
Other Metrics: The filing text does not provide current revenue, profit, cash flow, margins, debt, or liquidity figures. This report focuses solely on the capital raise event.
Material Changes
This filing reports a material change in the Company's capital structure through the issuance of new equity. The transaction involves existing stockholders who are accredited investors. The Company has agreed to enter into a Registration Rights Agreement, requiring the filing of a resale registration statement within 10 business days of closing and its effectiveness within 30 calendar days (or 75 days in the event of a full SEC review).
Guidance, Outlook, and Risks
Management Commentary: The Company intends to utilize the net proceeds to advance its clinical development for DM199, a preeclampsia treatment candidate.
Risks and Contingencies:
- Closing Conditions: The transaction is subject to the satisfaction of customary closing conditions.
- Registration Obligations: The Company faces potential liquidated damages if it fails to meet specified filing deadlines or maintain the effectiveness of the Resale Registration Statement.
- Liabilities: The Company agreed to indemnify selling holders under the Resale Registration Statement from certain liabilities.
Investor Verification Checklist
- Verify the actual closing date and final net proceeds after deducting offering expenses.
- Confirm the dilution impact of the 8,606,426 new shares on existing shareholders.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific representations and warranties.
- Monitor the filing and effectiveness status of the Resale Registration Statement to ensure compliance with the 30-day deadline.
- Assess the current cash runway and specific milestones for the DM199 preeclampsia program funded by this capital.